Skip to main content
. 2000 Jul 1;106(1):63–72. doi: 10.1172/JCI9586

Figure 4.

Figure 4

Effect of MR1 or CTLA4Ig treatment on cardiac allograft survival in wild-type (a) or CD28–/– mice (b). Recipients were treated with MR1 (250 μg intraperitoneally) on the day of transplantation or with CTLA4Ig (250 μg intraperitoneally) on day 2. Untreated controls are shown by solid line. AP < 0.01; BP = 0.33.